賽生藥業(06600.HK)盈喜:預計2021財年純利不少於9.15億元
格隆匯2月25日丨賽生藥業(06600.HK)發佈公吿,集團截至2021年12月31日止年度,預期集團將於2021財政年度錄得不少於人民幣9.15億元的公司未經審核股東應占盈利,而2020財政年度的股東應占盈利則約為人民幣7.54億元。此增長主要由於自有產品日達仙的迅速銷售以及授權引入產品的商業化。
公吿稱,上述利潤的影響部分被下列因素所抵銷:(i)日達仙臨牀研究及在研候選產品的研發成本於2021財政年度有所增加;及(ii)由於銷售及營銷團隊的擴展,以及市場發展及業務推廣活動因COVID-19爆發中斷而導致於2020財政年度錄得低點,因此銷售及營銷開支有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.